Role of PET/CT in ovarian cancer

American Journal of Roentgenology

Volumn 194, Issue 6, 2010, Pages

  Prakash, Priyanka ^a   Cronin, Carmel G ^a   Blake, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ovarian cancer; PET CT

Indexed keywords

BENIGN TUMOR; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; IMAGING SYSTEM; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; METHODOLOGY; OVARY TUMOR; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953263391     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3843     Document Type: Review

References (15)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
2. Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med 2009; 23:107-112
3. Fenchel S, Grab D, Nuessle K. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223:780-788 (Pubitemid 34547598)
4. 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007; 28:589-595
5. Kitajima K, Murakami K, Yamasaki E. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008; 35:1912-1920
6. Mironov S, Akin O, Pandit-Taskar N, Hann LE. Ovarian cancer. Radiol Clin North Am 2007; 45:149-166
7. Greenlee RT, Hill Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51:15-36
8. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996; 7:361-364
9. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histological findings. Radiology 2004; 233:433-440 (Pubitemid 39423802)
10. 18F] FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007; 34:480-486
11. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs CT alone in ovarian cancer recurrence. Abdom Imaging 2008; 33:112-118
12. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun 2008; 29:1046-1051
13. Fagotti A, Fanfani F, Rositto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology 2008; 75:152-158
14. Mangili G, Picchio M, Sironi S. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007; 34:658-666 (Pubitemid 46669366)
15. Simcock B, Neesham D, Quinn M. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006; 103:271-276 (Pubitemid 44374699)